8 recruiting, 1 completed, 1 not yet recruiting. 3 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Recruiting 3 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Systemic Therapy: new trials by email Literature Review of Systemic Therapy trials Research Report on Systemic Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-23 |
| OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy Systemic therapy - Brain Metastasis, Stereotactic Radiosurgery | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 20 | 2026-05-27 | 2026-09-15 |
| Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer Cytoreductive Gastrectomy - Metastatic Gastric Cancer, Gastric Cancer | Not applicable | Recruiting | University Medical Center Ho Chi Minh City (UMC) | 250 | 2025-08-01 | 2025-08-27 |
| Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy) - OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC) | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 132 | 2025-07-21 | 2026-10-13 |
| Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma Ablation, system therapy - Advanced Hepatocellular Carcinoma, Lung Cancer | Recruiting | Sun Yat-sen University | 470 | 2024-10-04 | 2026-10-23 | |
| The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma TACE, Ablation, Lenvatinb - Recurrent Hepatocellular Carcinoma, Lenvatinib | Not applicable | Recruiting | Sun Yat-sen University | 116 | 2024-10-01 | 2024-12-03 |
| TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT Transjugular intrahepatic portosystemic shunt, Lenvatinib, PD-1 inhibitor - Hepatocellular Carcinoma, Portal Vein Tumor Thrombus | Not applicable | Recruiting | Sun Yat-sen University | 42 | 2024-10-01 | 2025-01-13 |
| HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Recruiting | First Hospital of China Medical University | 84 | 2024-09-16 | 2024-10-08 | |
| Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma Transarterial Chemoembolization, Systemic Therapy | Recruiting | Sun Yat-sen University | 500 | 2023-03-01 | 2025-01-23 | |
| Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC TKI, anti PD-1, XELOX chemotherapy - Advanced HCC, Systemic Therapy | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 68 | 2021-10-01 | 2025-05-20 |
Carcinoma, Hepatocellular (3) · Brain Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Stomach Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (6) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Adenocarcinoma (3) · Carcinoma (3) · Liver Diseases (3) · Liver Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
lenvatinib (2) · 130-nm albumin-bound paclitaxel (1) · Immune Checkpoint Inhibitors (1) · Portasystemic Shunt, Transjugular Intrahepatic (1) · Radiotherapy (1) · disitamab vedotin (1) · spartalizumab (1) · toripalimab (1)
Sun Yat-sen University (4) · First Hospital of China Medical University (1) · M.D. Anderson Cancer Center (1) · Shandong Cancer Hospital and Institute (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Tianjin Medical University Second Hospital (1) · University Medical Center Ho Chi Minh City (UMC) (1)
China (8) · United States (1) · Vietnam (1)
Feng Duan (2) · Feng Duan, MD (1) · Jinbo Yue, Doctor (1) · Thomas H Beckham, MD (1)